Research progress in targeted and immunotherapy for esophageal cancer

doi:10.3760/cma.j.cn371439-20240805-00008

Abstract

Abstract:

The early diagnosis rate of esophageal cancer is low， and most of the patients are already in the middle or late stage when diagnosed， making treatment difficult， shortening the survival period and resulting in an extremely poor prognosis. In recent years， the continuous development of targeted therapy and immunotherapy has significantly improved the survival rate and therapeutic effect of esophageal cancer patients. Analyzing the research progress of targeted therapy and immunotherapy for esophageal cancer is of great significance and can provide reference for guiding the treatment of esophageal cancer.

Key words: Esophageal neoplasms, Molecular targeted therapy, Immunotherapy, Treatment outcome

Huang Zhen, Yan Fei, Ma Yanling, Sun Jianhai. Research progress in targeted and immunotherapy for esophageal cancer[J]. Journal of International Oncology, 2025, 52(1): 53-59.

References 49

[1]	He S, Xia C, Li H, et al. Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors[J]. Sci China Life Sci, 2024, 67(1): 122-131. DOI: 10.1007/s11427-023-2423-1.
[2]	de Castro Junior G, Segalla JG, de Azevedo SJ, et al. A randomised phase Ⅱ study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial[J]. Eur J Cancer, 2018, 88: 21-30. DOI: 10.1016/j.ejca.2017.10.005.
[3]	Yang X, Zhai Y, Bi N, et al. Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: a phase Ⅱ clinical trial[J]. Chin J Cancer Res, 2021, 33(1): 53-60. DOI: 10.21147/j.issn.1000-9604.2021.01.06.
[4]	Rades D, Bartscht T, Hunold P, et al. Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2)[J]. Strahlenther Onkol, 2020, 196(9): 795-804. DOI: 10.1007/s00066-020-01646-4. pmid: 32533228
[5]	Ruhstaller T, Thuss-Patience P, Hayoz S, et al. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase Ⅲ trial (SAKK 75/08)[J]. Ann Oncol, 2018, 29(6): 1386-1393. DOI: 10.1093/annonc/mdy105. pmid: 29635438
[6]	Huang J, Fan Q, Lu P, et al. Icotinib in patients with pretreated advanced esophageal squamous cell carcinoma with EGFR over-expression or EGFR gene amplification: a single-arm, multicenter phase 2 study[J]. J Thorac Oncol, 2016, 11(6): 910-917. DOI: 10.1016/j.jtho.2016.02.020. pmid: 26980473
[7]	Luo H, Jiang W, Ma L, et al. Icotinib with concurrent radiotherapy vs radiotherapy alone in older adults with unresectable esophageal squamous cell carcinoma: a phase Ⅱ randomized clinical trial[J]. JAMA Netw Open, 2020, 3(10): e2019440. DOI: 10.1001/jamanetworkopen.2020.19440.
[8]	Wang ZQ, Wang DS, Wang FH, et al. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase Ⅱ study[J]. Invest New Drugs, 2021, 39(2): 516-523. DOI: 10.1007/s10637-020-01021-1.
[9]	Hu Z, Sun S, Zhao X, et al. Rh-endostatin plus irinotecan/cisplatin as second-line therapy for advanced esophageal squamous cell carcinoma: an open-label, phase Ⅱ study[J]. Oncologist, 2022, 27(4): 253-e312. DOI: 10.1093/oncolo/oyab078.
[10]	Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J]. BMC Cancer, 2010, 10: 529. DOI: 10.1186/1471-2407-10-529. pmid: 20923544
[11]	Zhao J, Lei J, Yu J, et al. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma[J]. Invest New Drugs, 2020, 38(2): 500-506. DOI: 10.1007/s10637-019-00866-5.
[12]	Yanwei L, Feng H, Ren P, et al. Safety and efficacy of apatinib monotherapy for unresectable, metastatic esophageal cancer: a single-arm, open-label, phase Ⅱ study[J]. Oncologist, 2020, 25(10): e1464-e1472. DOI: 10.1634/theoncologist.2020-0310.
[13]	Chu L, Chen Y, Liu Q, et al. A phase Ⅱ study of apatinib in patients with chemotherapy-refractory esophageal squamous cell carcinoma (ESO-Shanghai 11)[J]. Oncologist, 2021, 26(6): e925-e935. DOI: 10.1002/onco.13668. pmid: 33393167
[14]	Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. J Hematol Oncol, 2018, 11(1): 120. DOI: 10.1186/s13045-018-0664-7.
[15]	Huang J, Xiao J, Fang W, et al. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: a double-blind randomized phase 2 trial[J]. Cancer Med, 2021, 10(5): 1681-1689. DOI: 10.1002/cam4.3771.
[16]	Kong DH, Kim MR, Jang JH, et al. A review of anti-angiogenic targets for monoclonal antibody cancer therapy[J]. Int J Mol Sci, 2017, 18(8): 1786. DOI: 10.3390/ijms18081786.
[17]	Cunningham D, Stenning SP, Smyth EC, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial[J]. Lancet Oncol, 2017, 18(3): 357-370. DOI: 10.1016/S1470-2045(17)30043-8. pmid: 28163000
[18]	Safran HP, Winter K, Ilson DH, et al. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2022, 23(2): 259-269. DOI: 10.1016/S1470-2045(21)00718-X. pmid: 35038433
[19]	Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-697. DOI: 10.1016/S0140-6736(10)61121-X.
[20]	Hofheinz RD, Merx K, Haag GM, et al. FLOT versus FLOT/trastuzumab/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase Ⅱ trial of the AIO EGA study group[J]. J Clin Oncol, 2022, 40(32): 3750-3761. DOI: 10.1200/JCO.22.00380.
[21]	Tabernero J, Hoff PM, Shen L, et al. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase Ⅲ randomized clinical trial[J]. Gastric Cancer, 2023, 26(1): 123-131. DOI: 10.1007/s10120-022-01335-4.
[22]	McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer[J]. Drugs Today (Barc), 2015, 51(1): 7-20. DOI: 10.1358/dot.2015.51.1.2250387.
[23]	Kojima T, Shah MA, Muro K, et al. Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148. DOI: 10.1200/JCO.20.01888.
[24]	Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771. DOI: 10.1016/S0140-6736(21)01234-4.
[25]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)食管癌诊疗指南2024[M]. 北京: 人民卫生出版社, 2024.
[26]	Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(11): 1506-1517. DOI: 10.1016/S1470-2045(19)30626-6. pmid: 31582355
[27]	Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma[J]. N Engl J Med, 2022, 386(5): 449-462. DOI: 10.1056/NEJMoa2111380.
[28]	Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 832-842. DOI: 10.1016/S1470-2045(20)30110-8. pmid: 32416073
[29]	Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10): 916-925. DOI: 10.1001/jama.2021.12836. pmid: 34519801
[30]	Liu J, Yang Y, Liu Z, et al. Multicenter, single-arm, phase Ⅱ trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2022, 10(3): e004291. DOI: 10.1136/jitc-2021-004291.
[31]	Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial[J]. Cancer Cell, 2022, 40(3): 277-288.e3. DOI: 10.1016/j.ccell.2022.02.007.
[32]	Xu J, Li Y, Fan Q, et al. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)[J]. Nat Commun, 2022, 13(1): 857. DOI: 10.1038/s41467-022-28408-3. pmid: 35165274
[33]	Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial[J]. BMJ, 2022, 377: e068714. DOI: 10.1136/bmj-2021-068714.
[34]	Yan X, Duan H, Ni Y, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase Ⅱ study (TD-NICE)[J]. Int J Surg, 2022, 103: 106680. DOI: 10.1016/j.ijsu.2022.106680.
[35]	Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2023, 24(5): 483-495. DOI: 10.1016/S1470-2045(23)00108-0. pmid: 37080222
[36]	Shen L, Kato K, Kim SB, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase Ⅲ study[J]. J Clin Oncol, 2022, 40(26): 3065-3076. DOI: 10.1200/JCO.21.01926.
[37]	Mamdani H, Schneider B, Perkins SM, et al. A phase Ⅱ trial of adjuvant durvalumab following trimodality therapy for locally advanced esophageal and gastroesophageal junction adenocarcinoma: a big ten cancer research consortium study[J]. Front Oncol, 2021: 736620. DOI: 10.3389/fonc.2021.736620.
[38]	van den Ende T, de Clercq NC, van Berge Henegouwen MI, et al. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase Ⅱ feasibility trial (PERFECT)[J]. Clin Cancer Res, 2021, 27(12): 3351-3359. DOI: 10.1158/1078-0432.CCR-20-4443. pmid: 33504550
[39]	Lorenzen S, Götze TO, Thuss-Patience P, et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase Ⅱ/Ⅲ Dante/IKF-s633 trial[J]. J Clin Oncol, 2024, 42(4): 410-420. DOI: 10.1200/JCO.23.00975.
[40]	Li J, Chen Z, Bai Y, et al. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study[J]. Nat Med, 2024, 30(3): 740-748. DOI: 10.1038/s41591-024-02797-y. pmid: 38302715
[41]	国家食品药品监督管理局. 2023年12月08日药品批准证明文件送达信息发布[EB/OL]. (2023-12-08)[2024-07-21]. https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20231208152050137.html.
[42]	Bang YJ, Cho JY, Kim YH, et al. Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer[J]. Clin Cancer Res, 2017, 23(19): 5671-5678. DOI: 10.1158/1078-0432.CCR-17-0025.
[43]	Park S, Oh D, Choi YL, et al. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma[J]. Cancer, 2022, 128(11): 2148-2158. DOI: 10.1002/cncr.34176.
[44]	Lee DH, Kim HR, Keam B, et al. Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma[J]. Cancer Med, 2023, 12(15): 16066-16075. DOI: 10.1002/cam4.6260.
[45]	Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle[J]. Immunity, 2013, 39(1): 1-10. DOI: 10.1016/j.immuni.2013.07.012. pmid: 23890059
[46]	Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer[J]. Nat Rev Drug Discov, 2004, 3(5): 391-400. DOI: 10.1038/nrd1381. pmid: 15136787
[47]	Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature, 2014, 515(7528): 563-567. DOI: 10.1038/nature14011.
[48]	Zhang B, Qi L, Wang X, et al. Phase Ⅱ clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma[J]. Cancer Commun (Lond), 2020, 40(12): 711-720. DOI: 10.1002/cac2.12119.
[49]	Meng X, Wu T, Hong Y, et al. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 245-253. DOI: 10.1016/S2468-1253(21)00378-2.